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Impact of Residual Stenosis of Side Branch on Clinical Outcomes in Patients
treated with 1-stent technique for Coronary Bifurcation Lesions
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Background: In coronary bifurcation lesions, little is known about the effect of re-
sidual side branch (SB) stenosis after main vessel (MV) stenting on long-term clinical
outcomes.
Methods: A total of 2,897 consecutive patients who underwent percutaneous coro-
nary intervention using a drug-eluting stent for a coronary bifurcation lesion with a SB
 2.3 mm were enrolled from 18 centers in South Korea. Of these, we analyzed data
from 1,563 patients who were treated with 1-stent technique for non-Left main
bifurcation lesions and ﬁnally have TIMI ﬂow grade 3 of the SB. We compared
cardiac death or myocardial infarction according to residual diameter stenosis (DS) of
the SB ostium in those patients.
Results: 574 patients have residual SB DS 50%, and 989 patients residual SB DS <
50% after the index procedure. During a median follow-up duration of 37 months,
patients with residual SB DS 50% have a higher incidence of cardiac death or
myocardial infarction (1.4 versus 3.3%, p¼0.01) than those with residual SB DS <
50%. Multivariate analysis revealed a higher risk of cardiac death or myocardial
infarction (hazard ratio [HR], 2.52; 95% conﬁdence interval [CI], 1.20-5.28; P¼0.02)
in the residual SB DS 50% group compared to the residual SB DS < 50% group.Table. Clinical Outcomes.
n¼1,563
rSB DS
<50%
rSB DS
50% Unadjusted HR p
Value
Adjusted HR p
Value
(n¼989) (n¼574) (95% CI) (95% CI)
All cause death 26 (2.6) 20 (3.5) 1.48 (0.83-2.66) 0.19 1.14 (0.61-2.12) 0.68
Cardiac death 6 (0.6) 7 (1.2) 2.14 (0.72-6.37) 0.17 1.82 (0.56-5.91) 0.32
MI 9 (0.9) 12 (2.1) 2.66 (1.12-6.31) 0.03 2.90 (1.15-7.32) 0.03
Cardiac death or
MI
14 (1.4) 19 (3.3) 2.63 (1.32-5.26) 0.01 2.52 (1.20-5.28) 0.02
Stent thrombosisy 3 (0.3) 3 (0.5) 1.87 (0.38-9.30) 0.44 1.44 (0.27-7.69) 0.67
TLR 62 (6.3) 39 (6.8) 1.22 (0.82-1.83) 0.33 1.26 (0.82-1.94) 0.29
*Adjusted covariates included history of chronic renal failure, bifurcation location, true
bifurcation, and SB DS before procedure.
yDeﬁnite or probable stent thrombosis.
TLF ¼ cardiac death, MI, or TLR
CDMI ¼ cardiac death or MI; CI ¼ conﬁdence interval; HR ¼ hazard ratio; MI ¼ myocardial
infarction; TLF ¼ target lesion failure; TLR ¼ target lesion revascularization.Conclusions: In patients treated with 1-stent technique for non-left main coronary
bifurcation lesions, residual SB DS 50% may be associated with a worse clinical
outcome compared to residual SB DS < 50%. These ﬁndings need to be conﬁrmed in
randomized controlled trials.
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Background: To evaluate the clinical and angiographic outcome of mini-crush
stenting for the treatment of true coronary bifurcation lesions. Percutaneous treatment
of coronary bifurcations lesions (CBL) is associated with a low procedural success rate
and high incidence of target lesion revascularization (TLR), and stent thrombosis. The
provisional approach is accepted as the default technique, but stent implantation on
both branches of the bifurcations is still required in 15%-30% of cases. The “mini-
crush” is one of the techniques used to implant stents on both branches of a CBL and
provides complete coverage of the ostium of the side branch, while minimizing the
length of the crushed stent. Data about outcomes for this technique are limited.
Methods: Between January 2006 and December 2012, 98 consecutive patients un-
derwent implantation of DES with mini-crush technique for the treatment of true CBL.
Clinical follow-up at our out-patient clinic was performed at 1-year. For the ﬁrst 50
patients an angiographic control was scheduled at 9 months.
Results: Clinical presentation was an acute coronary syndrome (ACS) in 71% of the
cases and stable coronary artery disease in the remaining 29%. Unprotected left main
was treated in 27% of patients. Two-step kissing balloon inﬂation and ﬁnal kissing
balloon inﬂation was systematically performed. First-generation DES were used in
90% of patients. Immediate procedural success was obtained in all of the cases. One
episode of deﬁnite stent thrombosis was documented 10 days after the index proce-
dure (premature DAP discontinuation). No deaths were documented. The 1-year cu-
mulative incidence of MACE was 5%: 2 episodes of myocardial infarction, and 3JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Corepeat procedure of revascularization. Angiographic restenosis was documented in 8%
(4/50 patients) and was localized at the ostium of the side branch in all of the cases.
Conclusions: Our results suggest that the treatment of bifurcation lesions by means of
mini-crush stenting technique is associated with excellent immediate success and
provides good angiographic and clinical outcomes at 1-year in a high-risk patients
population.
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Background: The strut thickness and deliverability of bioresorbable vascular scaffold
(BVS) may lead to more challenging for bifurcation lesions. Furthermore, all data
concerning BVS feasibility for bifurcation lesions are still limited.
Methods: We analyzed clinical outcome data of patients treated with BVS between
May 2012 and May 2014. The measured end-points were cardiac death, follow-up
myocardial infarction (MI), target lesion revascularization (TLR), target-vessel
revascularization (TVR) and major adverse cardiac events (MACE) deﬁned as com-
bination of cardiac death, follow-up MI and TVR.
Results: A total of 100 consecutive bifurcation lesions were successfully treated in 85
patients. The mean age was 62.8  11.6 years, and 88.6 % were males. Of these
lesions, 69 lesions were bifurcation lesions involving left anterior descending artery
(LAD) / diagonal branch and 5 lesions involved left main bifurcation lesions. True
bifurcation lesions (Medina classiﬁcation [1,1,1], [1,0,1], [0,0,1]) were observed in 64
lesions. Provisional single-stenting technique was used in 76 bifurcation lesions,
systematic double stenting technique was applied in 18 bifurcations with double BVS
in 13 lesions and mixed BVS-DES in 5 lesions (T-stenting in 11 lesions; Mini-crush
technique in 6 lesions; V-stenting technique in one lesion). Meticulous lesion prep-
aration with dedicated devices was needed in 19 lesions. Angiographic success was
achieved in 99.0%. At median follow-up of 231 days after the procedure, the overall
rates of cardiac death, MI, TLR, TVR and MACE were 0%, 1.2%, 5.9%, 7.1% and
8.2%, respectively. Deﬁnite stent thrombosis occurred in one case after discontinua-
tion of dual antiplatelet therapy.
Conclusions: Our results suggest that the treatment with BVS is feasible and effective
in a real life setting of bifurcation lesions, despite thick strut (> 150 mm) scaffolds and
limitation of side-branch access. Improvements in scaffold design may reduce the
need for meticulous lesion predilatation with dedicated devices and increase the
spectrum of lesions amenable to treatment with BVS.
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Background: PCI of bifurcation lesions is associated with higher rates of restenosis
and stent thrombosis compared to non-bifurcation lesions. In the e-BioMatrix registry
we compared the 2 year outcomes of bifurcation and non-bifurcation lesions treated
with one or more BioMatrix or BioMatrix Flex drug-eluting stents (BES). These
stents have an abluminal biodegradable polymer coating that releases Biolimus A9.
The coating fully absorbs within 6-9 months of implantation.
Methods: A total of 504 patients had PCI of at least one bifurcation lesion, 4968
patients were in the non-bifurcation subgroup. The primary endpoint was Major
Adverse Cardiovascular Events (MACE) deﬁned as a composite of cardiac death,
myocardial infarction (MI) and clinically-indicated target vessel revascularization (ci-
TVR) at 12 months. Secondary endpoints were MACE at 30 days, 6 months, 2 and 3
years, stent thrombosis (ST), major bleeding (MB) and total revascularization rates at
30 days, 6 months, 12 months, 2 and 3 years. Dual anti-platelet therapy (DAPT)
treatment was mandatory for 6 months and recommended up to 12 months.
Results: Clinical follow-up at 2 years was obtained in 95.2% of the bifurcation
subgroup and 93.7% of the non-bifurcation subgroup. DAPT compliance at 2 years
was of 30.9% vs. 30.5% respectively (p¼NS). A single stent strategy was employed in
79.9% of patients. MACE rates at 2 years were 10.9% vs. 6.4% (p< 0.001) in the
bifurcation and non-bifurcation groups, respectively. This difference was driven
principally by MI (4.7% vs. 2.2%, p< 0.001) and ci-TVR (8.1% vs. 3.9%, p< 0.001)
with no difference in cardiac death (1.2% vs. 1.5%, p¼0.6). Both peri-procedural
(1.6% vs. 0.4%, p¼0.002) and spontaneous MIs (2.3% vs. 1.1%, p¼0.02) wereronary Lesions - Bifurcations B55
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was similar (1.4% vs. 0.7%, p¼0.08). Of the 7 cases of ST in the bifurcation sub-
group, 6 occurred in patients treated with a 2 stent strategy.
Conclusions: These preliminary results suggest that BES’s perform well in bifurca-
tion lesions and that ST seems to be inﬂuenced by the stenting strategy.
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Background: The coronary bifurcation lesions are still problematic issue in inter-
ventional cardiology and their occurrence is a marker of increased procedural and
long-term risk. The aim of present study was to compare clinical effectiveness and
safety of newest version of BiOSS stent – BiOSS Lim, in comparison with historical
version, covered with paclitaxel, BiOSS Expert.
Methods: From September 2009, all patients with coronary bifurcation lesions
deemed appropriate for implantation of dedicated bifurcation stent BiOSS (Bifurcation
Optimization Stent System, Balton, Poland) were included in prospective registry. The
patients were excluded if they had ST-segment elevation myocardial infarction
(STEMI), life expectancy less than one year, inability to take double antiplatelet
therapy for 12 months, with bifurcation lesions Medina 001 and patient requiring more
than one BiOSS stent implantation. All patients had clinical examination at 30 days
and every 3 months thereafter were contacted by phone call.
Results: A 106 patients were included - 80 patients with BiOSS Lim (sirolymus-
eluting) and 26 with BiOSS Expert (paclitaxel-eluting). The mean age was 6410,
71% males, 39% diabetics, 35% had previous MI, 43% had previous PCI, 13%
previous CABG. Most of the patients were in CCS class 3-4 or were unstable (68%).
Multivessel disease or left main distal bifurcation occurred in 76%. True bifurcation
lesions occurred in 51% (Medina xx1). There were 2 postprocedural myocardial in-
farctions (1.9%) (CK-MB elevation). Increase of tropoinin I >3xnormal was observed
in 18%. At mean follow-up of 12 months there were 2 deaths (2%) and 3 spontaneous
myocardial infarctions (2.8%). A 12 angiographic restenotic lesions were detected
(11.3%), of which 10 (9.4%) were treated by repeat angioplasty. In total, the rate of
major adverse cardiac events (death, myocardial infarction and repeat PCI) was 10.4%
(11 pts). The rate of TLR (5%) and MACEs (7.5%) with BiOSS Lim was signiﬁcantly
lower than in BiOSS Expert (p< .005)
Conclusions: The new sirolymus eluting dedicated coronary bifurcation stent BiOSS
Lim demonstrated marked superiority over its paclitaxel version, with excellent
clinical efﬁcacy and safety in mid-term follow-up.Coronary Lesions - CTO
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Background: Chronic total occlusion (CTO) represents one of the most challenging
lesion subset in interventional cardiology. The Italian Registry of Chronic Total Oc-
clusion (IRCTO) aims to provide current data on CTO prevalence, and on clinical and
angiographic characteristics and management of CTO patients. Moreover, it reports
the effect of CTO treatment strategy on long-term prognosis.
Methods: The IRCTO is a prospective real world multicentre registry, which enrolled
patients showing at least 1 CTO at coronary angiography in thirteen high volume
catheterization labs across Italy. Clinical and angiographic data of all CTO patients,
regardless of chosen treatment strategy (medical therapy [MT], percutaneous coronaryB56 JACC Vol 64/11/Suppl Bintervention [PCI], or coronary artery bypass grafting [CABG]), were collected into a
web database.In order to compare outcomes of patients undergoing different treatment
strategies, while minimizing the impact of treatment selection bias and potential
confounding, a rigorous adjustment by propensity score matching (PSM) was
performed.
Results: A total of 1,777 patients were enrolled, among these 826 (46,5%) patients
were managed by MT, 776 (43,7%) by PCI and the last 175 (9.8%) were referred to
CABG. At one year, patients undergoing successful PCI showed lower rate of
MACCE and cardiovascular death in comparison with patients treated with MT and
CABG (2.6% vs 8.2% and vs 6.9%, p< 0.001 and p< 0.01, and 1.4% vs 4.7% and vs
6.3%, p< 0.001 and p< 0.001 respectively). After PSM analysis patients treated with
PCI showed lower incidence of death, acute myocardial infarction and re-hospitali-
zation rate in comparison with MT (4.4% vs 1.5% p< 0.001, 2.9% vs 1.1% p¼0.03
and 4.4% vs 2.3% p¼0.04 respectively).
Conclusions: The present study provides current data on prevalence, characteristics
and management of CTO patients. More importantly, our data showed as percuta-
neous revascularization of a CTO leads to a signiﬁcantly improved survival rate and a
reduction in MACCE at 1-year follow-up in comparison with MT and/or CABG
management.
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Background: Clinical beneﬁt of successful chronic total occlusion (CTO) revascu-
larization by percutaneous coronary intervention (PCI) remains under discussion. This
study aimed to assess health-related quality of life (HRQL), functional status and
myocardial ischemia after successful CTO PCI.
Methods: Between 2012 and 2014, 106 eligible patients who were scheduled for PCI
of a true CTO were included in this prospective study. HRQL questionnaire, six-
minute walk test and CMR studies were plan to be performed before and at 6-month
follow-up of patients with successful PCI of CTO. HRQL, was assessed by the short
form 36-item (SF-36) health survey, which measure health across eight-dimension,
including physical and mental components. Functional status was assessed by the six-
minute walk test. Regarding CMR study, the severity of ischemia was assessed by
means of an ischemic score index (ISI) based on the 16-segment model of analysis of
the left ventricle and calculated from the following items (relative weight is given in
brackets): 1) extension of the defect (20%); 2) persistence along the duration of the
perfusion sequence (20%); 3) transmurality (20%); and 4) inducibility of contractile
regional dysfunction under adenosine (40%).
Results: CTO recanalization signiﬁcantly improved all the components of the HRQL
test during follow-up (n¼66): patients with successful procedure experienced less
physical activity limitation (p< 0.001), rarer general pain episodes (p< 0.001) and
greater mental aspects (p< 0.001). The distance walked in the six-minute test (n¼59)
improved at follow-up (405.4  115.3 pre-PCI vs. 451.4  106.2 meters post-PCI, p<
0.001. Post-PCI, chest pain episodes decreased after the six-minute test, p< 0.001. A
correlation was found between distance walked in the six-minute test and physical
components of HRQL, r¼0.58, p< 0.001. Finally, total ISI by CRM (n¼37) also
improved signiﬁcantly, after PCI (basal 20.5 9.9% vs. post-PCI 4  9.2, p< 0.001).
Conclusions: CTO recanalization leads to a reduction in inducible myocardial
ischemia assessed by CMR. Furthermore, patients signiﬁcantly improved health-
related quality of life and experienced less physical activity limitation, and chest pain
episodes.
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Background: Chronic total occlusion (CTO) percutaneous coronary intervention
(PCI) can provide signiﬁcant clinical beneﬁts, yet there is limited information on its
success and safety in unselected patient populations. We sought to describe
contemporary frequency, predictors, and outcomes of CTO PCI in the United States.
Methods: We analyzed the frequency and outcomes of CTO PCI compared to non-
CTO PCI in elective patients, and of successful vs. failed CTO PCI, between July 1
2009 and March 31 2013 in the NCDR CathPCI Registry. Generalized estimatingj September 13–17, 2014 j TCT Abstracts/Coronary Lesions - CTO
